Mesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million - MESO News | RalliesMesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million
M
MESO• FY26 results show stronger revenue and narrower loss
- Mesoblast posted FY2026 revenue of US$120.3 million, up from US$17.2 million a year earlier, on Ryoncil launch momentum.
- Net loss narrowed 44% to US$57.5 million; gross profit rose to US$103.6 million as product sales climbed to US$115.2 million.
- R&D expense increased to US$97.5 million; selling, general and administration costs rose to US$57.3 million.
- Net operating cash spend was US$43.8 million; cash and cash equivalents ended at US$103 million following a US$125 million credit-line facility.
- Management flagged Phase 3 treatment completion for rexlemestrocel-L in chronic low back pain, with top-line results expected mid-CY2027.
STDN
•
